CEMI.US
id: 589, Created by Stan Vick, Scout
Chembio Diagnostics (CEMI) $8.1 MM Securities Settlement
How it works?
- Company agreed to pay compensation to its investors, to avoid further litigation
- We help you to prepare documents and file for compensation
Claim deadline for this case already passed by, but we can still try and file for compensation for you
Claim payout
E.D. New York
Court20-CV-02706
Case number12 Mar 2020
Class period Start16 Jun 2020
Class period End23 Jun 2023
Claim deadlineChembio Diagnostics (CEMI) agreed to pay $8.1 million to settle a securities class action lawsuit to avoid further litigation.
The Complaint alleged that the Company and its Leaders participated in a scheme to deceive the market by misrepresenting the effectiveness of the Company's DPP COVID-19 test. This conduct artificially inflated the price of Chembio stock and constituted fraud or deceit against purchasers of Chembio stock. When the truth about the negative factors affecting Chembio's business became public, the price of Chembio stock significantly dropped, resulting in a material decline that removed the inflation from the stock price. As a result, investors who purchased Chembio stock suffered real economic losses.
Alleged Offence
Other
Suspected Party
Other
Security Type
Stocks
Trade Direction
Long
Filing date
18 June 2020
Lead plaintiff
Municipal Employees’ Retirement System of Michigan
Attorney
Robbins Geller Rudman & Dowd LLP (Melville, NY), Rolnick Kramer Sadighi LLP (New York, NY)
Defendants
Richard L. Eberly, Gail S. Page, Neil A. Goldman, Javan Esfandiari, Katherine I. Davis, Dr. Mary Lake Polan, Dr. John G. Potthoff
Judge
Hon. Allyne R. Ross
Administrator
Gilardi & Co LLC
Court hearing date
05 June 2023
Exclusion deadline
15 May 2023
Objection deadline
15 May 2023
Hearing deadline
15 May 2023
+$8,100,000
Total Settlement Amount